{"id":"NCT01786993","sponsor":"Abbott Medical Devices","briefTitle":"MultiPoint Pacing IDE Study","officialTitle":"MultiPoint Pacing IDE Study","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2013-04","primaryCompletion":"2015-04","completion":"2016-06","firstPosted":"2013-02-08","resultsPosted":"2016-09-30","lastUpdate":"2019-02-04"},"enrollment":506,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Heart Failure"],"interventions":[{"type":"DEVICE","name":"MultiPoint Pacing","otherNames":[]},{"type":"DEVICE","name":"Traditional Biventricular Pacing","otherNames":[]}],"arms":[{"label":"Multi-point pacing arm","type":"EXPERIMENTAL"},{"label":"Biventricular arm","type":"ACTIVE_COMPARATOR"}],"summary":"This IDE study is a prospective, randomized, double-blind, multi-center clinical study to evaluate the safety and efficacy of patient treatment with MPP compared to patient treatment with standard BiV pacing at 9 months.\n\nThe study will be conducted at a maximum of 50 investigational centers located in the United States. A maximum of 506 subjects implanted with the Quadripolar cardiac resynchronization therapy device (CRT-D) system will be enrolled in the study.","primaryOutcome":{"measure":"Freedom From System-related Complications Through 9 Months Compared to an Objective Performance Criterion","timeFrame":"Implant to 9 months","effectByArm":[{"arm":"BiV/MPP Patients","deltaMin":0.932,"sd":null}],"pValues":[{"comp":"OG000","p":null}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":11},"locations":{"siteCount":49,"countries":["United States"]},"refs":{"pmids":["33028082","29759832"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":4,"n":201},"commonTop":["Phrenic Nerve/Diaphragmatic Stimulation Related to LV Lead","Artifact Observed on Atrial Channel","LV Lead Elevated Pacing Thresholds","RA/RV Lead Oversensing","Pulse Generator Oversensing"]}}